Infantile myofibromatosis (IMF) is a rare benign disorder characterized by the formation of nodules composed of myofibroblasts. These tumors can occur both on the skin and in deep tissues, including internal organs. The disease is mainly observed in children under two years of age, but can also occur in adolescents. Infantile myofibromatosis often manifests itself as multiple lesions that can vary in size and location. Despite their benign nature, the tumors can behave aggressively in early childhood, which requires careful monitoring and timely intervention.
History of the disease and interesting historical facts
Infantile myofibromatosis was first described in the early 20th century, but its true nature and pathogenesis remained unclear for decades. In 1951, studies by Shnoll and Kasper identified the disease as a separate nosological entity. Less than 20 years ago, scientists found that myofibromatosis may be associated with certain genetic mutations, which opened up new avenues for diagnosing and treating the disease. Interestingly, the presence of myofibromas is not only used in pediatric practice: in recent years, its connection with rarer tumors in adults has been studied.
Epidemiology
Infantile myofibromatosis is a rare condition, with an estimated incidence of 1 in 100,000 live births. According to the literature, the incidence in newborns ranges from 0.5% to 2%. Most cases of the disease occur in children under 2 years of age, with boys being slightly more susceptible to this disease than girls. Statistics show that about 80% cases of myofibromatosis are registered in children in this age range, and the incidence decreases significantly with age.
Genetic predisposition to this disease
Although the exact mechanisms of the disease are not fully understood, the key genes involved in the development of infantile myofibromatosis are currently known. The main genetic changes are associated with mutations in genes encoding proteins responsible for the development of connective tissues. One of the most studied mutations is changes in the PDGFRB gene, which is involved in the process of cell adhesion and migration. This indicates that the disease has not only a genetic but also a molecular basis, which opens up new horizons for the development of specific therapies.
Risk factors for the development of this disease
There are a number of factors that may increase the likelihood of developing infantile myofibromatosis. These include:
- Genetic predisposition: Having relatives with the disease may increase your risk.
- Environmental factors: Exposure of the fetus to certain chemicals may contribute to the development of tumors.
- Hereditary burden: increased chances of developing the disease in the presence of concomitant genetic pathologies.
Each of these factors can influence the occurrence of the disease in combination with other accompanying circumstances.
Diagnosis of this disease
Diagnosis of infantile myofibromatosis includes several main stages:
- Main symptoms: presence of soft tissue tumors, often painless, with possible dysfunction of organs, depending on their location.
- Laboratory tests: At this point, it may be useful to obtain biopsy material for histological examination.
- Radiological examinations: ultrasound, MRI and CT help determine the size and location of tumors.
- Other types of diagnostics: tests for levels of specific markers.
- Differential diagnosis: It is necessary to exclude other types of tumors, such as rhabdomyosarcomas and neuroblastomas.
These key points allow doctors to make an accurate diagnosis and begin appropriate treatment.
Treatment
Treatment for infantile myofibromatosis may vary depending on the size and location of the tumors. The main approaches are:
- General treatment: monitoring the growth and development of tumors; if there are no symptoms, intervention may not be required.
- Pharmacological treatment: use of anti-inflammatory and other medications in the presence of pain syndrome or complications.
- Surgical treatment: indicated in cases where tumors cause functional impairment or aesthetic discomfort.
- Other treatments: In rare cases, radiation therapy may be considered.
The appropriate approach must be individualized depending on each specific case.
List of medications used to treat this disease
Treatment for infantile myofibromatosis may include:
- Ibuprofen - to relieve inflammation and pain.
- Diclofenac is a non-steroidal anti-inflammatory drug.
- Corticosteroids - used in severe cases to reduce inflammation.
- Surgical medications are anesthetics used for surgical interventions.
The use of these drugs should be carried out under the supervision of specialists.
Disease monitoring
Monitoring of infantile myofibromatosis includes the following aspects:
- Control stages: regular examinations with assessment of tumor growth and their impact on organ function.
- Prognosis: Most tumors tend to regress by the age of 3-5 years, however, if the course is aggressive, complications may develop.
- Complications: may include effects on adjacent organs and, in rare cases, malignancy of tumors.
It is important to maintain specialist supervision throughout the transition period through critical age stages.
Age-related features of the disease
Infantile myofibromatosis manifests itself differently depending on the age group:
- Newborns: Multiple lesions are more common and may require surgical removal.
- Children under 2 years of age: regression of many tumors is observed without surgical intervention.
- Adolescents: the incidence rate decreases significantly, cases of the disease become exceptional.
The age aspect requires an individual approach to treatment and monitoring to achieve the best results.
Questions and Answers
- What is infantile myofibromatosis? This is a rare benign disease characterized by the formation of nodules of myofibroblasts, most often in children.
- What are the main symptoms of the disease? The main symptoms include the presence of soft tissue tumors, functional disorders are possible, depending on their location.
- Can this disease be treated with medication? Yes, depending on the situation, medications may be used for therapy, but surgery is often the most effective.
- Why is disease monitoring important? Monitoring is necessary for timely assessment of tumor growth and identification of possible complications.
- Which age group is more susceptible to this disease? The disease most often occurs in children under 2 years of age, and the incidence decreases with age.
Advice from Dr. Oleg Korzhikov
In infantile myofibromatosis, it is important to remember the main thing: the disease often has a favorable prognosis and can regress. However, it is important to maintain regular monitoring by a specialist. If new tumors or changes in existing ones occur, it is important to promptly consult a doctor. Parents should also discuss the correct methods of monitoring the child's condition during regular check-ups. If tumors are found, do not panic, as most of them are benign and can be treated.
